Bevacizumab or laser for aggressive posterior retinopathy of prematurity

Blair, Michael P.; González, Josué M.; Snyder, Laura; Schechet, Sidney A.; Greenwald, Mark J.; Shapiro, Michael J.; Rodríguez, S

doi:10.4103/tjo.tjo_69_18

Cited by 17 publications

(9 citation statements)

References 47 publications

(55 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recurrence rate is higher in type 1 ETROP with RBZ as compared to BVZ,[ 38 ] and almost similar recurrence in APROP with either of the two drugs. [ 39 ] The majority of the respondents of the current survey (46.5%) preferred weekly follow-up. However, around one-third (36.3%) of respondents decided their follow-up schedule based on the disease severity.…”

Section: Discussionmentioning

confidence: 98%

Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society

Gangwe

Agrawal

Vinekar

et al. 2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To report the results of the survey for the role of anti-VEGF in the management of retinopathy of prematurity (ROP) among the members of Indian ROP (iROP) society. Methods: A questionnaire was designed in English using Google forms and its link was circulated to the members of the iROP society on their mobile numbers. The survey included questions pertaining to demographics, anti-VEGF agents, injection technique, post-injection follow-up, and documentation pertaining to their ROP practice. Anonymous responses were obtained and analyzed for individual questions. Results: 226 members of the society were contacted and 157 responded (69.4%) to the survey. 137 (87.2%) respondents used anti-VEGF in the management of ROP. Aggressive posterior ROP (APROP) was the most common indication (78, 52.7%). The procedure was carried out in the main operation room (102, 70.3%) simultaneously for both the eyes (97; 68%) under topical anesthesia (134; 86.4%) by most of the respondents. One-hundred thirteen (77.9%) respondents used half of the adult dose, irrespective of the agent used; however, more than half of them preferred bevacizumab (85, 54%). 53 (36.3%) respondents followed up infants as per disease severity rather than a fixed schedule while only 33 (23%) performed photo documentation. 151 (96.2%) respondents felt the need for guidelines regarding the usage of anti-VEGF in ROP. Conclusion: There is an increase in the trend towards the use of anti-VEGF in the management of severe ROP, particularly APROP. However, there are considerable variations among the ROP practitioners regarding the agent, dosage, follow-up schedule, and documentation, suggesting the need for uniform guidelines.

show abstract

Section: Discussionmentioning

confidence: 98%

Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society

Gangwe

Agrawal

Vinekar

et al. 2021

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In a recent study, Mintz-Hittner showed reactivation in 100% of eyes with APROP [17] while Blair et al found 41% reactivation in APROP eyes in their study. [18] This difference in reactivation may be because of higher levels of VEGFs in APROP eyes. Because of late reactivation up to 69 weeks+ after anti-VEGF treatment, longer-term follow-up is required.…”

Section: Discussionmentioning

confidence: 99%

Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment

Narnaware¹,

Bawankule²,

Raje³

2021

JOVR

View full text Add to dashboard Cite

Purpose: To study the success rate of LASER as a primary modality of treatment in aggressive posterior retinopathy of prematurity (APROP) cases. Methods: This is a prospective case series of 56 eyes of 28 preterm babies (males = 21) with APROP who underwent laser therapy. Babies were divided into groups on the basis of gestational age (GA), birth weight (BW), and postmenstrual age (PMA) at which treatment was performed. GA (in weeks): <28 (n = 7), 28–30 (n = 11), >30 (n = 10). BW (in grams): <1000 (n = 8), 1000–1200 (n = 10), >1200 (n = 10). PMA (in weeks): < 32 (n = 6), 32–34 (n = 18), >34 (n = 4). Success was calculated as complete regression of disease without need for any other modality of treatment such as anti-vascular endothelial growth factor (anti-VEGF) or pars plana vitrectomy. Results: The overall success rate was 94.64% (53/56). Two babies who needed additional modality of treatment were <28 weeks of GA (one eye) and 28–30 weeks (two eyes). One baby (one eye) was <1000 gm and the other (two eyes) was >1200 gm, while PMA at which additional treatment was needed was 30 weeks in one baby (one eye) and 33 weeks in the other (two eyes). Conclusion: In this era of anti-VEGF treatment, even in cases of APROP, LASER should still be considered as a primary modality of treatment, as it is a one-time treatment without the concern of systemic side effects and recurrent/persistent avascular zones.

show abstract

“…We would like to thank Dr. Samanta for interest in our recent manuscript regarding aggressive posterior retinopathy of prematurity (APROP). [1]…”

mentioning

confidence: 99%

Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”

Schechet

Rodríguez

Shapiro

et al. 2019

Taiwan J Ophthalmol

Self Cite

View full text Add to dashboard Cite

Bevacizumab or laser for aggressive posterior retinopathy of prematurity

Cited by 17 publications

References 47 publications

Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society

Anti-vascular endothelial growth factor in the management of retinopathy of prematurity: A survey among the members of Indian Retinopathy of Prematurity Society

Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment

Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”

Contact Info

Product

Resources

About